Report: Obesity Drug Discoveries: what the future holds TOC

Foreword
Executive summary
What is obesity?
- Defining obesity
- What causes obesity?
- What effects does obesity have?
  - Figure 1: Effects of obesity on health
  - Table 1. Relative risks of health problems associated with obesity
- The scale of the problem
- Prevalence of obesity
  - Figure 2. Estimated global prevalence of obesity
    - Highest prevalence of obesity
    - Prevalence in the US
    - Prevalence in the UK
    - Prevalence in Europe
    - Prevalence in Asia
    - Prevalence in developing countries
  - Figure 3. Percentage of households having both underweight and overweight members in seven countries
  - Figure 4. Country comparison - percentage of adults with normal BMI
- Childhood and future obesity
  - Figure 5. Percentage of population that is overweight
  - Figure 6. Predicted prevalence of obesity by 2025
- The economic burden
  - US
  - UK
  - Europe
  - Developing Countries
The obesity therapy market
- Competitor ratio analysis
  - Table 2. Competitor ratio analysis summary
Obesity management
- Controlling energy balance
- Achieving weight loss
  - Table 3. The benefits of a 10kg weight loss
  - Lifestyle modifications
  - Behaviour therapy
  - Pharmacotherapy
  - Surgery
- Approved drugs for obesity management
  - Table 4. History of drug treatments for obesity
  - Table 5. Anti-obesity drugs approved for short-term use
  - Table 6. Anti-obesity drugs approved for long-term use
- Acomplia
  - Approval History
  - Key Markets
  - Key Agreements
  - Clinical Trial Data
  - Safety Issues
  - Further Development
  - Sales
  - Sales Forecast
    - Figure 7. Acomplia reported and projected sales, 2006A-2012E (EUR million)
- Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
- Meridia/Reductil
  - Approval History
  - Key Markets
  - Key Agreements
  - Clinical Trial Data
    - Table 7. Percentage change in subject' s body weight at varying doses of sibutramine
    - Table 8. Health profile of subjects losing at least 5 per cent of body weight
  - Safety Issues
  - Further Development
- Xenical/alli
  - Approval History
  - Key Markets
  - Key Agreements
  - Patent History
  - Clinical Trial Data
  - Safety Issues
  - Further Development
  - Sales
  - Sales Forecast
    - Figure 8. Reported and projected sales of Xenical 2001A-2011E
- Regulatory authority guidelines for drug approval
  - Approval for additional indications
- Potential new drugs
  - Table 9. Novel drugs in development by Phase
  - Table 10. Novel drugs in development by company
Drugs in clinical development
- Figure 9. Estimated launch dates for profiled drugs
- Beta3 adrenergic receptor modulators
  - Table 11. Beta3 adrenergic receptor modulators in development
- KR P-204 (N-5984)
  - Safety Issues
  - Competitors
  - Launch Prediction
- Cannabinoid receptor modulators
  - Table 12. Cannabinoid receptor modulators in development:
- CP-945,598
  - Safety Issues
  - Competitors
  - Launch Prediction
- taranabant
  - Safety Issues
  - Competitors
  - Launch Prediction
- AVE 1625
  - Safety Issues
  - Competitors
  - Launch Prediction
- SLV 319
  - Key Agreements
  - Safety Issues
  - Competitors
  - Launch Prediction
Digestive inhibitors/lipid metabolism modulators
- Table 13. Digestive inhibitors/lipid metabolism modulators in development
- cetilistat
  - Key Agreements
  - Clinical Trial Data
  - Safety Issues
  - Further Developments
  - Launch Prediction
- Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
- 869682
  - Safety Issues
  - Competitors
  - Launch Prediction
- Histaminergic system modulators
  - Table 14. Histaminergic system modulators in development
- OBE 101
  - Table 15. Properties of OBE101 and histamine compared
  - Key Agreements
  - Clinical Trial Data
  - Safety Issues
  - Table 16. Adverse effects of OBE101 when compared to anti-obesity medications currently in use
  - Patent History
  - Further Development
  - Competitors
  - Launch Prediction
Hormone analogues
- Table 17. Hormone analogues in development
- pramlintide
  - Clinical Trial Data
  - Further Development
  - Safety Issues
  - Launch Prediction
- Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
- liraglutide
  - Clinical Trial Data
  - Safety Issues
  - Launch Prediction
- Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
- obinepitide
  - Patent History
  - Clinical Trial Data
  - Further Development
  - Safety Issues
  - Competitors
  - Launch Prediction
- PYY 3-36
  - Key Agreements
  - Patent History
  - Clinical Trial Data
  - Further Development
  - Safety Issues
  - Competitors
  - Launch Prediction
Monoamine reuptake inhibitors/5-HT receptor modulators
- Table 18. Monoamine reuptake inhibitors/5-HT receptor modulators in development
- lorcaserin
  - Patent History
  - Clinical Trial Data
    - Table 19. Incidence of FDA-defined valvulopathy
  - Further Development
  - Safety Issues
  - Launch Prediction
- Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
- tesofensine
  - Clinical Trial Data
  - Further Development
  - Safety Issues
  - Launch Prediction
- Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
Neuropeptide receptor modulators
- Table 20. Neuropeptide receptor modulators in development
- S-2367
  - Clinical Trial Data
  - Safety Issues
  - Launch Prediction
- Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
Combination drugs
- Table 21. Combination drugs in development
- Contrave
  - Patent History
  - Clinical Trial Data
  - Further Developments
  - Safety Issues
  - Launch Prediction
- Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
- Qnexa
  - Clinical Trial Data
  - Further Development
  - Safety Issues
  - Launch Prediction
- Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
- pramlintide+phentermine/sibutramine
  - Safety Issues
  - Competitors
  - Launch Prediction
- Empatic
  - Patent History
  - Clinical Trial Data
    - Table 22. Percentage change in body weight at week 24
    - Safety Issues
    - Launch Prediction
  - Competitor Ratio Analysis
  - Novelty/rationale for mechanism of action
  - Proof of concept/clinical data
  - Management/clinical expertise
  - Competition within the marketplace
  - Risks associated with drug development in therapeutic class
Recently-terminated programmes
- AMG 076
- AOD 9604
  - Clinical Trial Data
- CP-741952
- CYT 009-GhrQb
  - Clinical Trial Data
- oleoyl-estrone
  - Patent History
  - Clinical Trial Data
  - Further Development
- PF-431499
The future of obesity treatment
- Towards an all-encompassing cure; targeting the metabolic syndrome?
- Recent advances and future developments
- CD 36
- Targeting ghrelin
- Vaccines
- Gene therapy
- RNA interference
Conclusions
Sources
- Espicom sources
- Others

Obesity Drug Discoveries: what the future holds

Table of Contents